Chemomab Therapeutics Ltd. SEC filings CMMB
Chemomab Therapeutics Ltd. has 366 filings in SEC EDGAR's recent list, going back to Nov 7, 2011. Its latest annual report, Form 20-F, was filed on Mar 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on May 11, 2023, covering the quarter ended Mar 31, 2023. The most recent current report (Form 6-K) was filed on Nov 3, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-4/A | Filing | Oct 29, 2026 | — |
| S-4/A | Filing | Oct 19, 2026 | — |
| S-4 | Registration for a merger or exchange | Sep 25, 2026 | — |
| 424B5 | Prospectus supplement | Jul 25, 2025 | — |
| POS AM | Filing | Dec 2, 2024 | — |
| 424B5 | Prospectus supplement | Nov 15, 2024 | — |
| 424B3 | Prospectus | Sep 9, 2024 | — |
| F-3 | Shelf registration (foreign issuer) | Aug 23, 2024 | — |
| F-3/A | Filing | Oct 30, 2023 | — |
| F-3 | Shelf registration (foreign issuer) | Oct 16, 2023 | — |
| S-1/A | Amended registration statement | May 19, 2023 | — |
| S-1/A | Amended registration statement | Mar 22, 2023 | — |
| S-1/A | Amended registration statement | Mar 21, 2023 | — |
| S-1/A | Amended registration statement | Feb 22, 2023 | — |
| S-1/A | Amended registration statement | Feb 21, 2023 | — |
| S-1 | Registration statement | Jan 13, 2023 | — |
| S-8 | Employee stock plan registration | Aug 15, 2022 | — |
| 424B5 | Prospectus supplement | Apr 25, 2022 | — |
| S-8 | Employee stock plan registration | Sep 13, 2021 | — |
| S-3 | Shelf registration | Apr 30, 2021 | — |
| 424B3 | Prospectus | Apr 29, 2021 | — |
| S-3 | Shelf registration | Apr 15, 2021 | — |
| 424B3 | Prospectus | Feb 12, 2021 | — |
| S-4/A | Filing | Feb 10, 2021 | — |
| S-4 | Registration for a merger or exchange | Jan 13, 2021 | — |
| S-8 | Employee stock plan registration | Mar 17, 2020 | — |
| S-8 | Employee stock plan registration | Jul 22, 2019 | — |
| 424B4 | Prospectus | Feb 13, 2019 | — |
| F-1/A | Amendment no. 4 to form f-1 | Feb 11, 2019 | — |
| F-1/A | Amendment no. 3 to form f-1 | Feb 8, 2019 | — |
| F-1/A | Amendment no. 2 to form f-1 | Feb 5, 2019 | — |
| F-1/A | Amendment no.1 to form f-1 | Jan 31, 2019 | — |
| F-1 | Registration statement (foreign issuer) | Jan 7, 2019 | — |
| S-8 POS | Filing | Dec 27, 2012 | — |
| POS AM | Filing | Dec 17, 2012 | — |
| S-8 | Employee stock plan registration | Aug 15, 2012 | — |
| 424B3 | Prospectus | Jun 7, 2012 | — |
| F-4/A | Form f-4/a | Jun 5, 2012 | — |
| F-4/A | Form f-4/a | May 29, 2012 | — |
| F-4 | Form f-4 | Jan 24, 2012 | — |
Showing 40 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CMMB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Tel Aviv
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1534248
- Former names
- Anchiano Therapeutics Ltd. (until Mar 17, 2021); BioCancell Ltd. (until Nov 3, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.